Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Keryx has declared the results of the clinical activity of KRX-0401 (perifosine), the company's Akt-inhibitor for cancer, to be used as a treatment for advanced renal cell carcnoma. The study enrolled a total of 50 patients, and KRX-0401 showed single agent efficacy in patients who progressed after failing treatment either with a VEGF receptor inhibitor or after treatment with both a VEGF receptor inhibitor and an mTOR inhibitor.
Subscribe to our email newsletter
The primary endpoint of this study was clinical benefit, defined as response rate (RECIST), and progression-free survival (PFS) in RCC patients.
Ron Bentsur, CEO of Keryx, said: We believe that this single agent activity for perifosine once again demonstrates that perifosine is an active, novel agent with the potential to provide clinical benefit to patients with 2nd or 3rd line metastatic renal cell cancer. We look forward to evaluating future trial designs in patients with advanced renal cell carcinoma.